{"id":915163,"date":"2025-12-02T10:29:38","date_gmt":"2025-12-02T15:29:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/"},"modified":"2025-12-02T10:29:38","modified_gmt":"2025-12-02T15:29:38","slug":"first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/","title":{"rendered":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin"},"content":{"rendered":"
\n

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc.\u00a0(Nasdaq: KURA, \u201cKura\u201d), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI\u2122 (ziftomenib) has been completed. Under Kura\u2019s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, \u201cKyowa Kirin\u201d), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. <\/p>\n

\n About\u00a0Kura Oncology <\/strong>
\n
Kura Oncology\u00a0is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura\u2019s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI\u2122, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory\u00a0NPM1<\/em>-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https:\/\/kuraoncology.com\/<\/a>\u00a0and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>
\n
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura\u2019s expectations regarding the receipt and timing of a milestone payment under its collaboration and license agreement with Kyowa Kirin and future development matters. Factors that may cause actual results to differ materially include\u00a0risks related to Kyowa Kirin\u2019s ability to make the expected milestone payment, including on the anticipated timing; risks associated with the commercialization of KOMZIFTI; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cpromise,\u201d \u201cpotential,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201ccontinues,\u201d \u201cdesigned,\u201d \u201cgoal,\u201d or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Kura Contact<\/strong>\n <\/p>\n

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc.\u00a0(Nasdaq: KURA, \u201cKura\u201d), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI\u2122 (ziftomenib) has been completed. Under Kura\u2019s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, \u201cKyowa Kirin\u201d), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. About\u00a0Kura Oncology Kura Oncology\u00a0is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura\u2019s pipeline of small molecule drug … <\/p>\n

Continue reading “First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFirst U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc.\u00a0(Nasdaq: KURA, \u201cKura\u201d), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI\u2122 (ziftomenib) has been completed. Under Kura\u2019s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, \u201cKyowa Kirin\u201d), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. About\u00a0Kura Oncology Kura Oncology\u00a0is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura\u2019s pipeline of small molecule drug … Continue reading "First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T15:29:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin\",\"datePublished\":\"2025-12-02T15:29:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/\"},\"wordCount\":490,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/\",\"name\":\"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=\",\"datePublished\":\"2025-12-02T15:29:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/","og_locale":"en_US","og_type":"article","og_title":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk","og_description":"SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc.\u00a0(Nasdaq: KURA, \u201cKura\u201d), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI\u2122 (ziftomenib) has been completed. Under Kura\u2019s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, \u201cKyowa Kirin\u201d), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. About\u00a0Kura Oncology Kura Oncology\u00a0is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura\u2019s pipeline of small molecule drug … Continue reading \"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T15:29:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin","datePublished":"2025-12-02T15:29:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/"},"wordCount":490,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/","name":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=","datePublished":"2025-12-02T15:29:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTA1MyM3MzAwMTYyIzIwMTcxOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-u-s-commercial-sale-of-komzifti-triggers-135-million-milestone-payment-to-kura-oncology-under-collaboration-and-license-agreement-with-kyowa-kirin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First U.S. Commercial Sale of KOMZIFTI\u2122 Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}